Dr. Dalton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
12902 USF magnolia Drive
Tampa, FL 33612Phone+1 813-745-4673- Is this information wrong?
Summary
- Dr. William Dalton is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He is also the Founder of M2Gen. He received his medical degree from Indiana University School of Medicine and has been in practice for 37 years. He specializes in hematologic oncology and is experienced in myeloma, health information, and medical informatics. He was a past CEO, and Cancer Center Director of the Moffitt Cancer Center (2002-1012).
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Clinical Pharmacology, 1983 - 1985- University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1983 - 1985
- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1981 - 1983
Indiana University School of MedicineInternship, Internal Medicine, 1980 - 1981- Indiana University School of MedicineClass of 1980
Indiana University School of MedicinePhD, Toxicology/Pharmacology, 1972 - 1976- University of New MexicoBA, Chemistry/Philosophy, 1967 - 1971
Certifications & Licensure
AZ State Medical License 1981 - 2024
FL State Medical License 2000 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow American Association for the Advancement of Science (AAAS), 2018
- Florida Inventors Hall of Fame Florida Inventors HOF, 2016
- Fellow, National Academy of Inventors 2013
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsPlasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.A.G.M. Mostofa, Allison Distler, Mark B. Meads, Eva Sahakian, John Powers, Alexandra Achille, David Noyes, Gabriela Wright, Bin Fang, Victoria Izumi, John M. Koomen, R...> ;JCI Insight. 2021 Nov 18
- 16 citationsPersonalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC.Jacob G. Scott, Geoff Sedor, Jessica A. Scarborough, Michael W. Kattan, Jeffrey Peacock, G. Daniel Grass, Eric A. Mellon, Ram Thapa, Michael J. Schell, Anthony F. Wall...> ;Journal of Thoracic Oncology. 2021 Mar 1
- 9 citationsMelphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.Joel G. Turner, Yan Cui, Alexis Bauer, Jana L. Dawson, Juan A Gomez, Jongphil Kim, Christopher L. Cubitt, Taiga Nishihori, William S. Dalton, Daniel M. Sullivan> ;Cancer Research. 2020 Oct 6
- Join now to see all
Research History
- CEO M2Geninformatics research, cancer genomics2012 - 2022
- CEO and Center Director, Moffitt Cancer Center and University of ArizonaMechanisms of drug resistance in cancer with emphasis on the tumor microenvironment and myeloma and breast cancer1985 - 2022
Hospital Affiliations
H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
